SEARCH

SEARCH BY CITATION

References

  • 1
    Morphy R., Kay C., Rankovic Z. (2004) From magic bullets to designed multiple ligands. Res Focus Rev;9:641652.
  • 2
    Morphy R., Rankovic Z. (2009) Designing multiple ligands – medicinal chemistry strategies and challenges. Curr Pharm Des;15:587600.
  • 3
    Abdelhamid E.E., Sultana M., Portoghese P.S., Takemori A.E. (1991) Selective blockage of the delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther;258:299303.
  • 4
    Fundytus M.E., Schiller P.W., Shapiro M., Weltrowska H., Coderre T.J. (1995) Attenuation of morphine tolerance and dependence with the highly selective delta opioid receptor antagonist TIPP(psi). Eur J Pharmacol;286:105108.
  • 5
    Hepburn M.J., Little P.J., Gringas J., Khun C.M. (1997) Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rate. J Pharmacol Exp Ther;281:13501356.
  • 6
    Purington L.C., Pohozheva I.D., Traynor J.R., Mosberg H.I. (2009) Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties. J Med Chem;52:77247731.
  • 7
    Schiller P.W. (2009) Bi- or multifunctional opioid peptide drugs. Life Sci;86:598603.
  • 8
    Purington L.C., Sobczyk-Kojiro K., Pogozheva I.D., Traynor J.R., Mosberg H.I. (2011) Development and in vitro characterization of a novel bifunctional mu-agonist/delta-antagonist opioid tetrapeptide. J Chem Biol;6:13751381.
  • 9
    Anathan S., Kezar H.S., Carter R.L., Saini S.K., Rice K.C., Wells J.L., Davis P., Xu H., Dersch C.M., Bilsky E.J., Porreca F., Rothman R.B. (1999) Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphans. J Med Chem;42:35273538.
  • 10
    Anathan S., Khare N.K., Saini S.K., Seitz L.E., Bartlett J.L., Davis P., Davis P., Xu H., Dersch C.M., Bilsky E.J., Porreca F., Rothman R.B. (2004) Identification of opioid ligands possessing mixed mu agonist/delta antagonist activity among pyridomorphans derived from naloxone, oxymorphone, and hydromorphone. J Med Chem;47:14001412.
  • 11
    Balboni G., Guerrini R., Salvadori S., Bianchi C., Rizzi D., Bryant S.D. et al. (2002) Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem;45:713720.
  • 12
    Balboni G., Salvadori S., Guerrini R., Negri L., Giannini E., Jinsmaa Y. et al. (2002) Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem;45:55565563.
  • 13
    Cheng K., Kim I.J., Lee M.J., Adah S.A., Raymond T.J., Bilsky E.J. et al. (2007) Opioid ligands with mixed properties from substituted enatiomeric N-phenethyl-5-phenylmorphans: synthesis of mu-agonist delta-antagonist and delta-inverse agonists. Org Biomol Chem;5:11771190.
  • 14
    Heibel A.C., Lee Y.S., Bilsky E.J., Guivelis D., Deschamps J.R., Parrish D. et al. (2005) Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. J Med Chem;50:37653776.
  • 15
    Salvadori S., Guerrini R., Balboni G., Bianchi C., Bryant S.D., Cooper P.S. et al. (1999) Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism of mu antagonism. J Med Chem;42:50105019.
  • 16
    Yamamoto T., Nair P., Vagner J., Largent-Milnes T., Davis P., Ma S.W. et al. (2008) A structure-activity relationship study and combinatorial synthetic approach to C-terminal modified bifunctional peptides that are Delta/Mu Opioid receptor agonists and neurokinin 1 receptor antagonists. J Med Chem;51:13691376.
  • 17
    Schiller P.W., Fundytus M.E., Merovitz L., Weltrowska G., Nguten T.M.-D., Lemieux C. et al. (1999) The opioid mu agonist/delta antagonist DIPP-NH2(psi) produces a potent analgesic effect, no physical dependence and less tolerance than morphine in rate. J Med Chem;42:35203526.
  • 18
    Schmidt R., Vogel D., Mrestani-Klaus C., Brandt W., Neubert K., Chung N.N. et al. (1994) Cyclic beta-casomorphin analgoues with mixed mu agonist/delta antagonist properties: synthesis, pharmacological characterization and conformational aspects. J Med Chem;37:11361144.
  • 19
    Przydzial M.J., Pogozheva I.D., Ho J.C., Bosse K.E., Sawyer E., Traynor J.R. et al. (2005) Design of high affinity cyclic pentapeptide ligands for the kappa opioid receptors. J Pept Res;66:255262.
  • 20
    Fowler C.B., Pogozheva I.D., Lomize A.L., LeVine H., Mosberg H.I. (2004) Refinement of a homology model of the Mu-opioid receptor using distance constraints from Intrinsic and engineered zinc-binding sites. Biochemistry;43:87008710.
  • 21
    Fowler C.B., Pogozheva I.D., Lomize A.L., LeVine H., Mosberg H.I. (2004) Complex of an active Mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints. Biochemistry;43:1579615810.
  • 22
    Pogozheva I.D., Lomize A.L., Mosberg H.I. (1997) The transmembrane 7-alpha-bundle of Rhodopsin: distance geometry calculations with hydrogen bonding constraints. Biophysics;72:19631985.
  • 23
    Pogozheva I.D., Lomize A.L., Mosberg H.I. (1998) Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophysics;75:612634.
  • 24
    Pogozheva I.D., Przydzial M.J., Mosberg H.I. (2005) Homology modeling of opioid receptor-ligand complexes using experimental constraints. AAPS Journal;7:4357.
  • 25
    Pfeiffer A., Brantl V., Herz A., Emrich H.M. (1986) Psychotomimesis mediated by kappa opioid receptors. Science;233:774776.
  • 26
    Przydzial M.J., Pogozheva I.D., Andrews S.M., Tharp T.A., Traynor J.R., Mosberg H.I. (2005) Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa opioid receptor. J Pept Res;26:333342.
  • 27
    Lee K.O., Akil H., Woods J.H., Traynor J.R. (1999) Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol;32:330.
  • 28
    Husbands S.M., Neilan C.L., Broadbear J., Grundt P., Breeden S., Aceto M.D. et al. (2005) BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. Eur J Pharmacol;11:735.
  • 29
    Traynor J.R., Nahorski S.R. (1995) Modulation by mu-opioid agonists of guanosine-5′-O(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SHY5Y cells. Mol Pharmacol;84:854.
  • 30
    Kufareva I., Rueda M., Katritch V., Stevens R.C., Abagyan R., participants G.D. (2011) Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assesment. Structure;19:11081126.
  • 31
    Congreve M., Langmead C.J., Mason J.S., Marshall F.H. (2011) Progress in structure based drug design for G protein-coupled receptors. J Med Chem;54:42834311.
  • 32
    Michino M., Abola E., Participants G.D., Charles L.Brooks.I., Dixon J.S., Moult J. et al. (2008) Community-wide assesment of GPCR structure modeling and ligand docking. Nat Rev Drug Discov;8:455463.
  • 33
    Mosberg H.I., Omnaas J.R., Smith C.B., Medzihradsky F. (1988) Cyclic disulfide and dithioether-containing opioid tetrapeptides: development of a ligand with enhanced delta opioid receptor selectivity and potency. Life Sci;43:10131020.
  • 34
    Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Mathiesin J.M., Sunahara R.K. et al. (2012) Crystal structure of the mu opioid receptor bound to a morphinan antagonist. Nature;485:321326.
  • 35
    Wu H., Wacker D., Mileni M., Katritch V., Han G.W., Vardy E. et al. (2012) Structure of the human kappa opioid receptor in complex with JDTic. Nature;485:327332.
  • 36
    Granier S., Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Weis W.I., Kobilka B.K. (2012) Structure of the δ-opioid receptor bound to naltrindole. Nature;485:400404.
  • 37
    Lomize A.L., Flippen-Anderson J.L., George C., Mosberg H.I. (1994) Conformational analysis of the delta receptor selective cyclic opioid peptide Tyr-c[DCys-Phe-DPen]OH (JOM13). Comparison of X-ray cystallographic structures, molecular mechanics simulations, and 1H NMR data. J Am Chem Soc;116:429436.
  • 38
    Mosberg H.I., Fowler C.B. (2002) Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs. delta selectivity. J Pept Res;60:329335.